Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Reductions in LVEF tied to mortality in seniors with NSTEMI

15 Oct 2019

New-onset decreases in left ventricular ejection fraction (LVEF) is common among seniors with non-ST-segment elevation myocardial infarction (NSTEMI) and appears to amplify mortality risk, a recent study has found.

Researchers enrolled 6,287 elderly NSTEMI patients (mean age, 84.6±3.7 years; 50 percent male), of whom 60 percent had normal, 20 percent had mildly reduced, 14 percent had moderately reduced and 6 percent had severely reduced LVEF, respectively. Primary outcome was all-cause mortality.

Over a median follow-up of 2.4 years, 2,211 deaths occurred. The resulting incidence rates per category of LVEF reduction were 11, 16, 23 and 44 deaths per 100 person-years, respectively; 1,042 of these deaths occurred within 1 year of follow-up.

Adjusting for confounders showed that the risk of all-cause death was significantly higher in patients with mild (hazard ratio [HR], 1.44, 95 percent CI, 1.25–1.65), moderate (HR 1.93, 1.67–2.23) and severe (HR, 3.24, 2.74–3.85) reductions in LVEF, as compared with those who had normal LVEF.

LVEF reduction had a similar effect on short-term mortality. There were 306 deaths within 30 days of admission. Analysis according to LVEF categories showed that the respective incidence rates were 28, 48, 117 and 304 deaths per person-year in the normal, mild, moderate and severe reduction groups.

In particular, patients with moderate (HR, 3.59, 2.47–5.21) and severe (HR, 3.59, 2.47–5.21) LVEF reductions had strong and significant mortality risk exacerbations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.